HC Wainwright lowered shares of NeuroSense Therapeutics (NASDAQ:NRSN – Free Report) from a buy rating to a hold rating in a research report released on Monday, MarketBeat reports.
NRSN has been the topic of a number of other reports. Weiss Ratings restated a “sell (e+)” rating on shares of NeuroSense Therapeutics in a research note on Wednesday, October 28th. Roth Capital lowered shares of NeuroSense Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 12th. One investment analyst has rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, NeuroSense Therapeutics presently has a consensus rating of “Hold” and a consensus price target of $170.00.
Read Our Latest Research Report on NRSN
NeuroSense Therapeutics Price Performance
NASDAQ NRSN opened at $1.42 on Monday. The company has a fifty day moving average price of $5.07 and a 200-day moving average price of $12.61. NeuroSense Therapeutics has a 1 year low of $1.10 and a 1 year high of $25.40. The firm has a market cap of $2.70 million, a price-to-earnings ratio of -0.13 and a beta of 1.74.
Institutional Inflows and Outflows
A hedge fund recently bought a new position in NeuroSense Therapeutics stock. Yorkville Advisors Global LP acquired a new stake in NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 78,000 shares of the company’s stock, valued at approximately $56,160. Yorkville Advisors Global LP owned 0.21% of NeuroSense Therapeutics at the end of the most recent quarter. 1.04% of the stock is owned by institutional investors and hedge funds.
NeuroSense Therapeutics Company Profile
NeuroSense Therapeutics Ltd. is an Israel-based clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases. The company’s research is aimed at addressing multiple biological mechanisms associated with conditions such as amyotrophic lateral sclerosis (ALS), Alzheimer’s disease and Parkinson’s disease.
Its lead investigational product, PrimeC, is a proprietary oral combination formulation of ciprofloxacin and celecoxib designed to target pathways implicated in ALS, including neuroinflammation and RNA regulation.
See Also
- Five stocks we like better than NeuroSense Therapeutics
- Why ExxonMobil and Chevron Reminded Investors to Keep it Simple
- Amazon Has Erased Its Earnings Sell-Off, But Is the Biggest Opportunity Still Ahead?
- onsemi’s AI Sales Surge 175%: Is a Stock Recovery Next?
- Energy Transfer’s Earnings Miss May Be Hiding Its Strongest Advantage
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
